issues

November/December 2018

Download PDF

COVER

REGENERATIVE MEDICINE – Cell Therapy – The Quest for Finding the Cure

Aarti Chitale, MBA, believes as the therapeutic landscape evolves and transitions toward personalized and value-based care, regenerative medicine will play an increasingly important role, and moreover, the success of these therapies offers promising opportunities for previously untreated diseases areas.

FEATURES

HUMAN MICROBIOME – Advancing New Frontiers in a Rapidly Emerging Market

Flo Orim, MD, PhD, focuses on biomedical aspects of research, development, and commercial endeavors in the human microbiome space, including essential background information, evolution of the field, and advances in basic research.

REGENERATIVE MEDICINE – Cell Therapy – The Quest for Finding the Cure

Aarti Chitale, MBA, believes as the therapeutic landscape evolves and transitions toward personalized and value-based care, regenerative medicine will play an increasingly important role, and moreover, the success of these therapies offers promising opportunities for previously untreated diseases areas.

GENETIC MODIFICATION THERAPIES – Clinical Applications & Technology Platforms

Laurie L. Sullivan and John Bergin, MS, MBA, say the growing interest on the part of large pharma or biotech companies is driving clinical development of genetic modification therapy candidates, and the rich late-stage pipeline for genetic modification therapy candidates is a driving force of growth.

EXECUTIVE INTERVIEW – BD Integrated Systems: From Innovation to Integration

Theresa Bankston, PhD, Director of the Technical Services group for BD Medical – Pharmaceutical Systems, discusses the advantages of using an integrated system for complex drug-device combination products.

THERAPEUTIC VACCINES – Exploring the Potential of Combining Cancer Vaccines With Immune Checkpoint Inhibitor Therapy

Nina Baluja, MD, believes advances in our understanding of tumor immunology are rekindling interest in cancer vaccines, particularly in combination with breakthrough immunotherapies, such as immune checkpoint inhibitors.